Intact and c-terminal FGF23 assays-do kidney function, inflammation, and low iron influence relationships with outcomes?

19Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

Context: Higher fibroblast growth factor-23 (FGF23) concentrations are associated with heart failure and mortality in diverse populations, but the strengths of associations differ markedly depending up on which assay is used. Objective: We sought to evaluate whether iron deficiency, inflammation, or kidney function account for differences in the strengths of associations between these 2 FGF23 assays with clinical outcomes. Design: Case cohort study from the Cardiovascular Health Study. Setting: A total of 844 community-dwelling individuals aged 65 years or older with and without chronic kidney disease were followed for 10 years. Outcomes: Outcomes included death, incident heart failure (HF), and incident myocardial infarction (MI). Exposure was baseline intact and C-terminal FGF23. Using modified Cox models, adjusting sequentially we tested whether observed associations of each assay with outcomes were attenuated by iron status, inflammation, kidney function, or their combinations. Results: FGF23 measured by either assay was associated with mortality in unadjusted analysis (intact FGF23 hazard ratio [HR] per 2-fold higher 1.45; 95% CI, 1.25-1.68; C-terminal FGF23 HR 1.38; 95% CI, 1.26-1.50). Adjustment for kidney function completely attenuated associations of intact FGF23 with mortality (HR 1.00; 95% CI, 0.85-1.17), but had much less influence on the association of C-terminal FGF23, for which results remained significant after adjustment (HR 1.15; 95% CI, 1.04-1.28). Attenuation was much less with adjustment for iron status or inflammation. Results were similar for the HF end point. Neither C-terminal or intact FGF23 was associated with MI risk. Conclusions: The relationship of FGF23 with clinical end points is markedly different depending on the type of FGF23 assay used. The associations of biologically active FGF23 with clinical end points may be confounded by kidney disease, and thus much weaker than previously thought.

References Powered by Scopus

Estimating glomerular filtration rate from serum creatinine and cystatin C

3276Citations
N/AReaders
Get full text

FGF23 induces left ventricular hypertrophy

1708Citations
N/AReaders
Get full text

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

1520Citations
N/AReaders
Get full text

Cited by Powered by Scopus

An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk

48Citations
N/AReaders
Get full text

C-terminal and intact FGF23 in kidney transplant recipients and their associations with overall graft survival

21Citations
N/AReaders
Get full text

Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysis

10Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Sharma, S., Katz, R., Bullen, A. L., Chaves, P. H. M., De Leeuw, P. W., Kroon, A. A., … Ix, J. H. (2020). Intact and c-terminal FGF23 assays-do kidney function, inflammation, and low iron influence relationships with outcomes? Journal of Clinical Endocrinology and Metabolism, 105(12). https://doi.org/10.1210/clinem/dgaa665

Readers over time

‘20‘21‘22‘23‘24‘25036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

60%

Researcher 3

30%

Lecturer / Post doc 1

10%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

50%

Nursing and Health Professions 2

25%

Pharmacology, Toxicology and Pharmaceut... 1

13%

Chemistry 1

13%

Save time finding and organizing research with Mendeley

Sign up for free
0